Vaxxinity Inc (VAXX) Actualités

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and...

Form 15-12G - Securities registration termination [Section 12(g)]

Form DEF 14C - Other definitive information statements

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the...

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company...

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company...

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company...

Form 8-K - Current report

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety...

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company...

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company...